UK Markets close in 18 mins

AC Immune SA (ACIU)

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Add to watchlist
3.0400-0.0300 (-0.98%)
As of 10:56AM EDT. Market open.
Full screen
Loading interactive chart…
  • Globe Newswire

    AC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome

    Interim analysis expected around year-end 2022, informing Phase 2 startTrial progressing with regulatory clearances in the UK and also now in SpainPlanned submission of U.S. Investigational New Drug application in Q1 2023Continues progress towards prevention of neurodegenerative diseases LAUSANNE, Switzerland, Oct. 04, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today provided an up

  • Globe Newswire

    AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer’s Disease

    AC Immune’s Tau PET tracer moves closer to becoming a next generation diagnostic for Alzheimer’s Disease (AD)AC Immune to receive a milestone payment from LMI for progress into late-stage product development LAUSANNE, Switzerland, Sept. 26, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its partner, Life Molecular Imaging (LMI), is moving PI-2620, the Tau positron-

  • Globe Newswire

    AC Immune Receives a Grant from The Michael J. Fox Foundation for Continued Development of Parkinson’s Disease Diagnostic Imaging Agent

    Previously reported clinical proof-of-concept data on ACI-12589 showed the PET tracer generating the first live images of alpha-synuclein in the human brainNew grant funding will pave the way for enhanced clinical studiesTotal funding from The Michael J. Fox Foundation for AC Immune’s alpha-synuclein PET tracer program is now up to USD 3.7 million LAUSANNE, Switzerland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision